U.S. pharma large copyright scrapped two experimental weight loss drugs previous yr—a once-each day pill, lotiglipron, on account of elevated liver enzymes plus a 2 times-daily pill, danuglipron, due to powerful Unwanted side effects—but CEO Albert Bourla has stated the company is se